29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis

Key Takeaways Explain This Topic AI

Acute viral rhinosinusitis (AVRS) accounts for 90% to 98% of all acute rhinosinusitis episodes, whereas acute bacterial rhinosinusitis (ABRS) develops in only 2% to 10% of cases; routine empiric antibiotic therapy within the first 10 days violates Choosing Wisely guidelines and promotes antimicrobial resistance.

ABRS is clinically confirmed by one of three cardinal IDSA/AAO-HNS diagnostic patterns: (1) persistent symptoms >=10 days without clinical improvement, (2) severe presentation with high fever (>=39°C / 102.2°F) and purulent nasal discharge or facial pain for >=3-4 consecutive days at illness onset, or (3) 'double sickening' marked by acute recrudescence after 5-6 days of initial improvement.

First-line antimicrobial therapy for confirmed adult ABRS is oral amoxicillin-clavulanate 875/125 mg BID for 5 to 7 days; high-dose amoxicillin-clavulanate (2,000/125 mg extended-release BID) is required for adults >=65 years, recent antibiotic exposure (<30 days), recent hospitalization, systemic immunocompromise, or severe toxicity.

In penicillin-allergic patients, oral doxycycline (100 mg BID) or respiratory fluoroquinolones (levofloxacin 500 mg daily or moxifloxacin 400 mg daily) are the evidence-based alternatives; macrolides (azithromycin), TMP-SMX, and first-generation cephalosporins must be strictly avoided due to widespread Streptococcus pneumoniae resistance (>30-40%).

Topical nasal decongestants (oxymetazoline 0.05%) must be limited to <=3 to 5 consecutive days to prevent rhinitis medicamentosa; proptosis, diplopia, ophthalmoplegia, periorbital edema, or meningismus represent life-threatening orbital or intracranial complications mandating emergent contrast-enhanced CT/MRI and parenteral broad-spectrum antibiotics.

Last updated: September 2026

Epidemiology & Clinical Anatomy of Rhinosinusitis

Acute rhinosinusitis is defined as symptomatic inflammation of the mucosal lining of the nasal cavity and paranasal sinuses lasting fewer than 4 weeks. Because the mucous membranes of the paranasal sinuses are continuous with the respiratory epithelium of the nasal passages, pure sinusitis without concurrent rhinitis virtually never occurs; hence, the term rhinosinusitis is preferred in clinical practice and clinical guidelines.

Rhinosinusitis is one of the leading diagnoses in ambulatory family medicine, responsible for more than 20 million outpatient visits and upwards of 15% to 20% of all adult antibiotic prescriptions in the United States. However, an immense epidemiological mismatch exists between clinical presentation and antimicrobial prescribing:

Acute Viral Rhinosinusitis (AVRS) : Represents 90% to 98% of all acute rhinosinusitis presentations in adults.

Acute Bacterial Rhinosinusitis (ABRS) : Accounts for only 2% to 10% of adult episodes, typically arising as a secondary bacterial complication following an antecedent viral upper respiratory infection (URI) or allergic inflammation.

Functional Anatomy of the Paranasal Sinuses

The paranasal sinuses comprise four paired, air-filled bony cavities lined with pseudostratified ciliated columnar epithelium: the maxillary , frontal , anterior/posterior ethmoid , and sphenoid sinuses. Normal sinus physiology relies upon three essential pillars: (1) ostial patency, (2) coordinated ciliary apparatus function, and (3) adequate mucus quality and hydration.

The critical anatomical crossroad is the ostiomeatal complex (OMC) , located within the middle meatus beneath the middle turbinate. The OMC serves as the shared drainage pathway for the anterior ethmoid air cells, the maxillary sinus (via its natural ostium situated high on its superomedial wall, requiring ciliary transport against gravity), and the frontal sinus (via the frontonasal duct). Because the drainage channels of the OMC are narrow (often 1 to 2 mm in diameter), even modest mucosal edema rapidly produces mechanical ostial occlusion. OSTIOMEATAL COMPLEX DRAINAGE PATHWAY

• [Frontal Sinus] [Anterior Ethmoid Air Cells]
• │ │
• ▼ ▼
• (Frontonasal Duct) (Infundibulum)
• │ │
• └───────────────┬────────────────┘
• ▼
• [MIDDLE MEATUS / OMC]
• ▲
• │
• (Maxillary Sinus Ostium)
• │
• [Maxillary Sinus]

*Ostial caliber <=1-2 mm: Minimal mucosal edema causes mechanical obstruction,

hypoxia, impaired ciliary clearance, mucus stasis, and secondary bacterial growth.

Pathophysiology of Sinus Obstruction & Secondary Infection

Viral Inoculation & Mucosal Injury : Respiratory viruses (predominantly rhinovirus, coronavirus, influenza, parainfluenza, and respiratory syncytial virus [RSV]) bind to respiratory epithelial cells, triggering inflammatory mediator release (interleukin-1, IL-6, IL-8, and tumor necrosis factor-alpha). This cascade produces extensive mucosal hyperemia, intercellular edema, and transudative fluid production.

Ciliary Dysfunction & Ostial Occlusion : Viral cytopathology causes shedding of ciliated epithelial cells and transient ciliary dyskinesia. Mucosal tumescence within the narrow ostiomeatal channels obstructs sinus outflow.

Intrasinus Stasis & Hypoxia : Trapped intrasinus secretions suffer progressive oxygen absorption, resulting in profound sinus cavity hypoxia and acidosis. This hostile microenvironment paralyzes remaining ciliary beat frequency and promotes secondary bacterial adherence.

Secondary Bacterial Overgrowth (ABRS) : When transient nasopharyngeal commensals enter the obstructed, stagnant sinus cavity, bacterial proliferation accelerates. The primary pathogens implicated in adult ABRS are:

Streptococcus pneumoniae (30% to 35%): Gram-positive diplococci; historically dominant, though intermediate and high-level penicillin resistance mediated by altered penicillin-binding proteins (PBPs) remains a critical therapeutic concern.

Haemophilus influenzae (non-typeable, 30% to 35%): Gram-negative coccobacilli; increased in prevalence following widespread pneumococcal conjugate vaccination. Approximately 30% to 40% of strains produce beta-lactamase.

Moraxella catarrhalis (10% to 15%): Gram-negative diplococci; >90% to 95% produce beta-lactamase.

Staphylococcus aureus and anaerobic organisms ( Peptostreptococcus , Prevotella , Fusobacterium ): Infrequently encountered in acute community-acquired ABRS, but prominent in odontogenic maxillary sinusitis , which accounts for approximately 10% to 15% of unilateral maxillary sinusitis cases secondary to periapical dental abscesses or periodontal disease involving the maxillary premolars or molars.

Clinical Differentiation: The Three Cardinal Diagnostic Patterns

Because viral and bacterial rhinosinusitis share nearly identical initial symptoms—including nasal congestion, purulent rhinorrhea, facial pain/pressure, maxillary dental ache, postnasal drip, headache, and fatigue—clinical differentiation cannot rely upon symptom characteristics alone.

Important

Purulent (thick, discolored, green or yellow) nasal discharge does NOT indicate bacterial infection! In viral colds, the influx and lysis of neutrophils with enzymatic release of myeloperoxidase naturally turns nasal secretions opaque and greenish-yellow on days 2 to 4 of illness.

To prevent gross overprescribing of antibiotics, the Infectious Diseases Society of America (IDSA) and the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) have established three rigorous clinical patterns that define Acute Bacterial Rhinosinusitis (ABRS): IDSA / AAO-HNS DIAGNOSTIC CRITERIA FOR ABRS

• ┌─────────────────────────────────────────────────────────────────────────┐
• │ Pattern 1: PERSISTENT SIGNS & SYMPTOMS (>=10 Days) │
• │ • Nasal discharge, congestion, or facial pain lasting >=10 days │
• │ • NO evidence of clinical improvement whatsoever │
• ├─────────────────────────────────────────────────────────────────────────┤
• │ Pattern 2: SEVERE ONSET (>=3-4 Consecutive Days) │
• │ • High fever (>=39.0°C / 102.2°F) │
• │ • Purulent nasal discharge AND/OR severe focal facial pain │
• │ • Present concurrently for >=3-4 consecutive days at illness onset │
• ├─────────────────────────────────────────────────────────────────────────┤
• │ Pattern 3: 'DOUBLE SICKENING' (Biphasic Course) │
• │ • Typical viral URI that begins to improve or resolve after 3-5 days │
• │ • Sudden acute recrudescence with new fever, severe headache, │
• │ increased facial pain, or worsening purulent rhinorrhea on days 5-8 │
• └─────────────────────────────────────────────────────────────────────────┘
• 1. Persistent Symptoms (>=10 Days)

Viral upper respiratory infections typically peak in severity between days 3 and 5 and progressively resolve within 7 to 10 days. Therefore, signs and symptoms of acute rhinosinusitis (nasal obstruction, anterior/posterior purulent drainage, facial pressure/pain) that persist for 10 or more days without any subjective or objective clinical improvement indicate secondary bacterial infection.

2. Severe Symptoms at Onset (>=3-4 Consecutive Days)

Unlike typical viral colds that present with low-grade fever and mild malaise, ABRS may manifest as an aggressive acute infection. Severe presentation requires high fever (temperature >=39.0°C or 102.2°F) accompanied by purulent nasal discharge or focal unilateral facial pain for at least 3 to 4 consecutive days at the start of illness.

3. 'Double Sickening' (Biphasic Illness)

This hallmark pattern reflects an initial uncomplicated viral rhinosinusitis that begins to improve after 3 to 5 days, followed by acute secondary deterioration between days 5 and 8. Patients report sudden onset of new or higher fever, severe unremitting headache, intensifying unilateral maxillary or frontal facial pain, or dramatic escalation of purulent nasal secretions.

The Choosing Wisely Campaign & Antibiotic Stewardship

The American Board of Internal Medicine (ABIM) Foundation and the American Academy of Family Physicians (AAFP) under the Choosing Wisely campaign provide unambiguous recommendations regarding acute rhinosinusitis:

Avoid Routine Radiologic Imaging : Plain sinus radiographs (Waters, Caldwell, lateral views) have unacceptably low sensitivity and specificity and must not be performed. Even non-contrast paranasal sinus CT scans show mucosal thickening, air-fluid levels, and sinus opacification in over 80% to 90% of patients with uncomplicated viral colds . Routine CT imaging leads to unnecessary ionizing radiation exposure, excessive financial cost, and spurious diagnostic confirmation that drives inappropriate antibiotic use. CT imaging is strictly reserved for suspected orbital or intracranial complications.

Avoid Routine Antibiotic Therapy for Uncomplicated Sinusitis <10 Days : Because >90% of rhinosinusitis cases are viral, prescribing antibiotics before day 10 exposes patients to adverse drug reactions (severe diarrhea, Clostridioides difficile colitis, cutaneous eruptions, anaphylaxis) without clinical benefit.

Natural History & The Option for Watchful Waiting : Even among patients who strictly fulfill the 10-day diagnostic criteria for ABRS, approximately 60% to 75% achieve spontaneous clinical cure within 7 to 14 days through endogenous immune clearance. The AAO-HNS guidelines recommend offering watchful waiting (initial observation for up to 7 days) to reliable adult patients with mild-to-moderate ABRS who have ready access to follow-up care, utilizing delayed ('safety-net') antibiotic prescriptions if symptoms fail to improve.

Evidence-Based Antimicrobial Pharmacotherapy

When antibiotic therapy is indicated for ABRS, antimicrobial selection must account for the high prevalence of beta-lactamase-producing H. influenzae and M. catarrhalis , alongside penicillin-resistant S. pneumoniae (PRSP). ABRS ANTIMICROBIAL SELECTION ALGORITHM

• Confirmed ABRS (Meets 1 of 3 Criteria)
• │
• ▼
• Penicillin Allergy Assessment
• │
• ┌──────────────────────┴──────────────────────┐
• ▼ ▼
• NO ALLERGY TRUE PENICILLIN ALLERGY
• │ │
• High-Risk Features?* ┌───────┴───────┐
• ┌───────┴───────┐ ▼ ▼
• ▼ ▼ Doxycycline Levofloxacin
• NO YES 100 mg BID 500 mg Daily
• Standard Dose High-Dose x 5-7 Days x 5-7 Days
• Amox-Clav Amox-Clav (Preferred) (Severe/Failed)
• 875/125 mg BID 2,000/125 mg BID
• x 5-7 Days x 7-10 Days

*High-risk features: Age >=65y, prior abx in past 30 days, recent hospitalization,

immunocompromised state, severe systemic toxicity (T >=39°C), or PRSP rate >=10%.

First-Line Regimen: Standard-Dose Amoxicillin-Clavulanate

Regimen : Amoxicillin-clavulanate (Augmentin) 875/125 mg PO BID for 5 to 7 days in adults.

Why not amoxicillin monotherapy? Amoxicillin alone provides excellent coverage against S. pneumoniae , but lacks stability against the beta-lactamases produced by 30% to 40% of non-typeable H. influenzae and >90% of M. catarrhalis . The addition of the beta-lactamase inhibitor clavulanate restores full activity.

Duration : Randomized trials demonstrate that a 5- to 7-day course is therapeutically equivalent to traditional 10- to 14-day courses in uncomplicated adult ABRS, while substantially reducing gastrointestinal side effects and selective pressure for resistance.

High-Dose Amoxicillin-Clavulanate Regimen

Regimen : Amoxicillin-clavulanate 2,000/125 mg extended-release PO BID for 7 to 10 days (or standard amoxicillin-clavulanate supplemented with pure amoxicillin to deliver 2,000 mg amoxicillin BID with 125 mg clavulanate BID).

Indications for High-Dose Augmentin :

• Age >=65 years;
• Systemic antibiotic exposure within the preceding 30 days;
• Hospitalization within the past 5 days;
• Immunocompromised host (diabetes mellitus, chronic kidney disease, active immunosuppression);
• Severe infection (fever >=39.0°C, systemic toxicity, severe unilateral facial pain);

High local endemic prevalence of penicillin-non-susceptible S. pneumoniae (>=10%).

Penicillin-Allergic Regimens

In patients with a documented, convincing penicillin allergy:

First-Line Penicillin-Allergic Choice : Doxycycline 100 mg PO BID for 5 to 7 days .

Doxycycline demonstrates excellent in vitro activity against S. pneumoniae , non-typeable H. influenzae , and M. catarrhalis .

It exhibits low resistance rates, minimal risk of selecting for multi-drug resistant pathogens, and favorable cost and tolerability profiles.

Respiratory Fluoroquinolones : Levofloxacin 500 mg PO once daily OR Moxifloxacin 400 mg PO once daily for 5 to 7 days .

Reserved for patients who cannot tolerate doxycycline, those with high-risk features, or those failing initial therapy.

Fluoroquinolones carry FDA black-box warnings for tendinitis, tendon rupture (Achilles tendon), peripheral neuropathy, central nervous system toxicities, aortic dissection, and QT interval prolongation.

Clinical Regimen Dosage & Route Duration Clinical Rationale & Pearls

First-Line Standard Amoxicillin-clavulanate 875/125 mg PO BID 5–7 days First-line choice; covers beta-lactamase producers ( H. influenzae , M. catarrhalis ) and S. pneumoniae

First-Line High-Risk Amoxicillin-clavulanate 2,000/125 mg ER PO BID 7–10 days Indicated for age >=65, prior abx <30d, immunocompromised, or severe presentation

Penicillin Allergy (Primary) Doxycycline 100 mg PO BID 5–7 days Preferred alternative; excellent coverage across all major pathogens; low cost

Penicillin Allergy (Alternative) Levofloxacin 500 mg daily OR Moxifloxacin 400 mg daily 5–7 days Respiratory fluoroquinolones; reserve for severe disease or doxycycline failure

CONTRAINDICATED: Macrolides Azithromycin, Clarithromycin Do NOT use >30% to 40% S. pneumoniae resistance; unacceptable bacteriologic failure rates

CONTRAINDICATED: TMP-SMX Trimethoprim-sulfamethoxazole Do NOT use >30% to 50% S. pneumoniae and H. influenzae resistance; high treatment failure

CONTRAINDICATED: 1st Gen Ceph Cephalexin 500 mg PO QID Do NOT use Inadequate coverage against H. influenzae and M. catarrhalis

Caution

Antimicrobial Regimens to Strictly Avoid in ABRS :

Macrolides (Azithromycin, Clarithromycin) : Upwards of 30% to 40% of S. pneumoniae isolates in North America possess macrolide resistance (mediated by mefA efflux pumps or ermB ribosomal methylation). The ubiquitous 'Z-pack' must NEVER be prescribed for ABRS.

Trimethoprim-Sulfamethoxazole (TMP-SMX) : Resistance rates among S. pneumoniae and H. influenzae exceed 30% to 50%.

Oral Cephalosporin Monotherapy : First-generation cephalosporins (cephalexin) lack activity against H. influenzae . Second- and third-generation oral cephalosporins (cefdinir, cefuroxime axetil, cefpodoxime) have variable pneumococcal coverage and should not be used as monotherapy unless combined with clindamycin.

Symptomatic Management & The Danger of Rhinitis Medicamentosa

Symptomatic and adjunctive therapies should be offered to all patients with acute rhinosinusitis, whether viral or bacterial:

Intranasal Saline Irrigation : Large-volume, low-pressure saline rinses (using isotonic or hypertonic sterile/distilled water delivered via neti pot or squeeze bottle) mechanically flush inspissated mucus, reduce mucosal edema, liquefy crusted secretions, and facilitate mucociliary transport. Highly recommended as an adjunct by both IDSA and AAO-HNS.

Intranasal Corticosteroids (INCS) : Fluticasone propionate (2 sprays per nostril daily) or mometasone furoate (2 sprays per nostril daily) suppresses local mucosal cytokines, decreases ostiomeatal inflammation, and accelerates ostial reopening. Particularly beneficial in individuals with underlying allergic rhinitis or chronic rhinosinusitis.

Analgesics and Antipyretics : Acetaminophen (500 to 1,000 mg every 6 hours as needed, max 3,000 to 4,000 mg/day) and ibuprofen (400 to 600 mg every 6 to 8 hours with meals) effectively control facial pain, pressure, and fever.

Oral Decongestants (Pseudoephedrine) : Provides modest subjective decongestion via alpha-adrenergic vasoconstriction of capacitance vessels. Caution is warranted in patients with systemic arterial hypertension, arrhythmias, closed-angle glaucoma, and benign prostatic hyperplasia.

Oral Antihistamines : Strictly NOT recommended in non-allergic acute rhinosinusitis. Anticholinergic drying effects thicken intrasinus secretions and impair ciliary clearance, worsening sinus outflow obstruction.

The Critical Warning: Oxymetazoline & Rhinitis Medicamentosa

Topical intranasal vasoconstrictor sprays such as oxymetazoline 0.05% (Afrin) act directly on post-junctional alpha-1 and alpha-2 adrenergic receptors on nasal capacitance venules, producing rapid and profound mucosal decongestion within minutes.

The Rule of 3 to 5 Days : Oxymetazoline use must be strictly restricted to no more than 3 to 5 consecutive days .

Pathophysiology of Rhinitis Medicamentosa : Prolonged continuous stimulation of alpha-adrenergic receptors triggers rapid receptor down-regulation, desensitization, and tachyphylaxis. Concurrently, local ischemia and rebound endogenous beta-receptor-mediated vasodilation ensue. Upon medication cessation, the patient suffers severe, intractable rebound chemical vasodilatation, intense interstitial edema, and severe nasal obstruction .

Clinical Presentation : The patient presents with complete, relentless nasal obstruction that is refractory to standard decongestants, accompanied by dry, hyperemic, 'beefy-red' hypertrophic nasal mucosa. Patients enter an addiction-like cycle of spraying oxymetazoline every 2 to 3 hours just to breathe.

Treatment of Rhinitis Medicamentosa : Immediate and complete cessation of the topical decongestant. To manage severe rebound obstruction during withdrawal, initiate high-dose intranasal corticosteroids (e.g., fluticasone 2 sprays each nostril BID), aggressive saline irrigations, and in severe cases, a short tapering course of oral corticosteroids ( prednisone 30 to 40 mg daily tapered over 5 to 7 days ).

Sight- and Life-Threatening Complications: Orbital & Intracranial Red Flags

The paranasal sinuses share intimate anatomical relationships with the orbits and the intracranial vault, separated only by thin bony partitions and valve-less diploic veins (veins of Breschet):

The ethmoid sinus is separated from the orbit by the paper-thin lamina papyracea ; ethmoiditis is the primary source of pediatric and adult orbital complications.

The frontal sinus posterior table abuts the anterior cranial fossa; frontal sinusitis can breach the bone to form a subperiosteal abscess of the frontal bone ( Pott's puffy tumor ) or extend intracranially.

The sphenoid sinus is enveloped by the cavernous sinuses, internal carotid arteries, and cranial nerves III, IV, V1, V2, and VI. RED FLAGS IN ACUTE RHINOSINUSITIS

• ORBITAL COMPLICATIONS INTRACRANIAL COMPLICATIONS
• Axial Proptosis • Severe, Unremitting Frontal Headache
• Pain with Extraocular Motion • Altered Mental Status / Lethargy
• Diplopia (Gaze Limitation) • High Spiking Fevers with Rigors
• Decreased Visual Acuity • Meningismus (Nuchal Rigidity)
• Afferent Pupillary Defect • Focal Neurological Deficits / Seizures
• Marked Periorbital Chemosis • Bilateral Orbital Signs (Cavernous Sinus)
• │ │
• └───────────────┬───────────────┘
• ▼
• EMERGENCY INTERVENTIONS (MANDATORY)
• 1. STAT Contrast-Enhanced CT / MRI of Orbits & Sinuses
• 2. Emergent ENT & Ophthalmology Consultation
• 3. Hospital Admission for IV Broad-Spectrum Antibiotics
• (Vancomycin + Ceftriaxone + Metronidazole)
• 4. Emergent Surgical Drainage if Abscess / Vision Loss
• Chandler Classification of Orbital Complications

Orbital extension of acute rhinosinusitis progresses through five distinct pathological stages defined by Chandler:

Chandler Stage Pathological Process Distinctive Clinical Findings Emergency Management

Stage I: Preseptal Cellulitis Edema and inflammation anterior to the orbital septum Eyelid edema and erythema; normal visual acuity, normal pupillary light reflexes, full and painless extraocular motility, NO proptosis Outpatient or inpatient oral/IV antibiotics (amoxicillin-clavulanate or ampicillin-sulbactam)

Stage II: Orbital Cellulitis Diffuse post-septal infection of orbital fat without distinct abscess Axial proptosis, chemosis, painful limitation of extraocular movements (ophthalmoplegia), diplopia ; visual acuity preserved Immediate hospital admission, IV broad-spectrum antibiotics (Vancomycin + Ceftriaxone)

Stage III: Subperiosteal Abscess (SPA) Purulent collection between periorbita and lamina papyracea Marked proptosis, displacement of globe (inferolaterally), severe limitation of gaze, decreased visual acuity Urgent surgical drainage (endoscopic or external) + IV antibiotics

Stage IV: Orbital Abscess Discrete pus collection within the orbital fat cone Severe proptosis, complete ophthalmoplegia, profound vision loss, relative afferent pupillary defect (Marcus Gunn pupil) STAT emergent surgical orbitotomy / endoscopic decompression + IV antibiotics

Stage V: Cavernous Sinus Thrombosis Retrograde septic thrombophlebitis via superior/inferior ophthalmic veins Bilateral orbital signs , bilateral proptosis, rapid chemosis, involvement of CN III, IV, V1, V2, VI (loss of corneal reflex), high fever, toxemia STAT contrast MRI/MRV or CT; IV Vancomycin + Cefepime + Metronidazole; urgent anticoagulation consultation

High-Yield Board Pearls: Acute Rhinosinusitis

The 10-Day Rule : Never prescribe antibiotics for uncomplicated sinus symptoms present for fewer than 10 days unless the patient displays severe onset (T >=39°C + purulence/pain for >=3-4 consecutive days) or 'double sickening'.

Macrolide Myth : Macrolides (azithromycin) are completely inappropriate for ABRS due to 30% to 40% pneumococcal resistance. A patient demanding a 'Z-pack' for acute sinusitis must be redirected.

Odontogenic Origin : A patient presenting with unilateral, foul-smelling maxillary sinus discharge with facial pressure must have their maxillary dentition evaluated; up to 15% of maxillary sinusitis arises from periapical molar infections requiring dental extraction or root canal along with anaerobic coverage.

Oxymetazoline Limitation : Limit topical oxymetazoline to <=3 to 5 days to prevent rhinitis medicamentosa. When present, treat with cessation of oxymetazoline, high-dose intranasal corticosteroids, and an oral steroid taper.

Pott's Puffy Tumor : A fluctuant, doughy swelling on the forehead with fever indicates subperiosteal abscess of the frontal bone secondary to frontal osteomyelitis, requiring emergent imaging and intravenous antibiotics.

Vision Loss is a Surgical Emergency : Any decrease in visual acuity or appearance of an afferent pupillary defect in a patient with sinusitis signifies impending optic nerve ischemia from orbital apex compression, requiring emergent surgical decompression.

Loading diagram... Clinical Decision Algorithm for Acute Rhinosinusitis